Legend Biotech Corporation: 1Q26 EPS - Putting the CAR in Drive

Research evidence excerpt

Legend Biotech Corporation: 1Q26 EPS - Putting the CAR in Drive

ity.

United Kingdom: Approved and/or distributed by Deutsche Bank AG acting through its London Branch at 21

Moorfields, London EC2Y 9DB. Deutsche Bank AG in the United Kingdom is authorised by the Prudential Regulation

Authority and is subject to limited regulation by the Prudential Regulation Authority and Financial Conduct Authority.

Details about the extent of our authorisation and regulation are available on request.

Hong Kong SAR: Distributed by Deutsche Bank AG, Hong Kong Branch, except for any research content relating to

futures contracts within the meaning of the Hong Kong Securities and Futures Ordinance Cap. 571. Research reports

on such futures contracts are not intended for access by persons who are located, incorporated, constituted or

resident in Hong Kong. The author(s) of a research report may not be licensed to carry on regulated activities in Hong

Kong, and if not licensed, do not hold themselves out as being able to do so. The provisions set out above in the

'Additional Information' section shall apply to the fullest extent permissible by local laws and regulations, including

without limitation the Code of Conduct for Persons Licensed or Registered with the Securities and Futures

Commission. This report is intended for distribution only to 'professional investors' as defined in Part 1 of Schedule of

the SFO. This document must not be acted or relied on by persons who are not professional investors. Any investment

or investment activity to which this document relates is only available to professional investors and will be engaged

only with professional investors.

India: Prepared by Deutsche Equities India Private Limited (DEIPL) having CIN: U65990MH2002PTC137431 and